GlassScriptPhysician profile
Melanie Grgurich
NPI 1316922214
$3,194.53
in general payments reported to CMS, 2019-2025
34 companies · $253 in 2025
The $253 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $950 · 2020: $97.16 · 2021: $280 · 2022: $957 · 2023: $359 · 2024: $299 · 2025: $253.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $911.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $910.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $571.67 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $327.15 | 2019-2024 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $234.72 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $198.94 | 2019-2025 | Breztri, Farxiga |
| Dexcom, INC. | $197.93 | 2022-2023 | Dexcom G6 Transmitter |
| Pfizer INC. | $186.61 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $168.78 | 2019-2021 | |
| Allergan, INC. | $129.93 | 2019-2020 | |
| Amgen INC. | $123.12 | 2019-2024 | Otezla, Repatha |
| Supernus Pharmaceuticals, INC. | $117.42 | 2019-2023 | Qelbree |
| Abbott Laboratories | $113.24 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Bayer Healthcare Pharmaceuticals INC. | $111.02 | 2022-2024 | |
| E.R. Squibb & Sons, L.L.C. | $97.60 | 2019-2023 | Eliquis |
| Nevro Corp. | $91.57 | 2022-2023 | Senza |
| Merck Sharp & Dohme LLC | $55.00 | 2019-2025 | Verquvo, Proquad, Vaxelis |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $52.67 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $40.99 | 2019 | |
| Janssen Pharmaceuticals, INC | $40.41 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $36.03 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $34.31 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.67 | 2019-2022 | |
| Ironshore Pharmaceuticals INC. | $26.98 | 2019-2024 | |
| Mylan Specialty L.P. | $24.26 | 2019-2022 | |
| Grifols USA, LLC | $24.21 | 2019 | |
| Glaxosmithkline, LLC. | $24.09 | 2019-2021 | |
| Gilead Sciences, INC. | $19.20 | 2019 | |
| Shire North American Group INC | $18.20 | 2019 | |
| Sunovion Pharmaceuticals INC. | $18.13 | 2022 | |
| Tandem Diabetes Care, INC. | $17.66 | 2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Ardelyx, INC. | $15.22 | 2024 | Ibsrela |
| Exact Sciences Corporation | $13.58 | 2024 | Cologuard Collection Kit |
| Kowa Pharmaceuticals America, INC. | $13.53 | 2025 | Zoryve |
| Melinta Therapeutics, LLC | $13.30 | 2019 | |
| Phathom Pharmaceuticals, INC. | $7.39 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melanie Grgurich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.